> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Joint Panel to Review InfaCare Pharma NDA
- URL: https://www.fdaweb.com/fda-joint-panel-to-review-infacare-pharma-nda/
- Published: 2018-03-28T12:00:00.000Z
- Updated: 2026-09-14T23:55:55.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5141088

*Federal Register* notice: FDA has announced a 5/3 joint Gastrointestinal Drugs Advisory Committee and Pediatric Advisory Committee meeting. Panel members are scheduled to review an InfaCare Pharmaceutical NDA for stannsoporfin intramuscular injection, indicated for treating neonates greater than or equal to 35 weeks of gestational age with indicators of hemolysis who are at risk of developing severe hyperbilirubinemia. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2018-03-28/pdf/2018-06168.pdf?ref=fdaweb.com).